Loading
SHR-1501 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.
SHR-1501 is an investigational agent whose form is not stated in the registry developed by Suzhou Suncadia Biopharmaceuticals and Shanghai Hengrui Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07424287 (A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC) and NCT07726992 (A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC), in bladder & urothelial cancer. The largest, NCT07726992, plans to enrol 750 participants with primary completion expected 2029-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.SHR-1501 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SHR-1501" OR ABSTRACT:"SHR-1501") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SHR-1501, not a curated reading list.
Shares A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC, Bladder & urothelial cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Bladder & urothelial cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Bladder & urothelial cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Bladder & urothelial cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.